Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Indaptus Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
INDP
Nasdaq
8731
https://indaptusrx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Indaptus Therapeutics Inc
Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
- Apr 11th, 2024 11:30 am
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference
- Mar 28th, 2024 12:00 pm
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
- Mar 25th, 2024 12:30 pm
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024
- Mar 18th, 2024 12:00 pm
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
- Mar 13th, 2024 11:30 am
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
- Mar 4th, 2024 12:30 pm
Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference
- Feb 15th, 2024 1:00 pm
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
- Feb 8th, 2024 1:00 pm
European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology
- Jan 4th, 2024 1:00 pm
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 6th, 2023 9:01 pm
Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study
- Nov 6th, 2023 1:00 pm
Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting
- Oct 31st, 2023 1:01 pm
Indaptus Therapeutics to Present at the LD Micro Main Event XVI
- Sep 27th, 2023 12:00 pm
Registration Is Now Open For Tribe Public’s Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics’ CEO On Friday, September 29, 2023
- Sep 26th, 2023 12:00 pm
Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20
- Sep 19th, 2023 12:00 pm
Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Sep 6th, 2023 12:05 pm
Favourable Signals For Indaptus Therapeutics: Numerous Insiders Acquired Stock
- Aug 29th, 2023 12:44 pm
Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Aug 14th, 2023 12:00 pm
Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20
- Aug 10th, 2023 12:45 pm
Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer
- Aug 7th, 2023 12:00 pm
Scroll